Many groups are working to discover new, safer ways to deliver drugs that fight cancer to the tumor without damaging healthy cells. Others are finding ways to boost the body’s own immune system to attack cancer cells. For the first time, researchers at Penn State have combined the two approaches by conjugating biodegradable polymer nanoparticles encapsulated with chosen cancer-fighting drugs into immune cells to create a smart, targeted system to attack cancers of specific types.
“The traditional way to deliver drugs to tumors is to put the drug inside some type of nanoparticle and inject those particles into the bloodstream,” said Jian Yang, professor of biomedical engineering, Penn State. “Because the particles are so small, if they happen to reach the tumor site they have a chance of penetrating through the blood vessel wall because the vasculature of tumors is usually leaky.”
The odds of interacting with cancer cells can be improved by coating the outside of the nanoparticles with antibodies or certain proteins or peptides that will lock onto the cancer cell when they make contact. However, this is still a passive drug delivery technology. If the particle does not go to the tumor, there is no chance for them to bind and deliver the drug.
Yang and Cheng Dong, department head and distinguished professor of biomedical engineering, wanted a more active method of targeting drugs to the cancer wherever it was located, whether circulating in the blood, or in the brain or in any of the other organs of the body.
“I have 10 years of working in immunology and cancer,” Dong said. “Jian is more a biomaterials scientist. He knows how to make the nanoparticles biodegradable. He knows how to modify the particles with surface chemistry, to decorate them with peptides or antibodies. His material is naturally fluorescent, so you can track the particles at the same time they are delivering the drug, a process called theranostics that combines therapy and diagnostics. On the other hand, I study the cancer microenvironment, and I have discovered that the microenvironment of the tumor generates kinds of inflammatory signals similar to what would happen if you had an infection.”
Immune cells, which were built to respond to inflammatory signals, will be naturally attracted to the tumor site. This makes immune cells a perfect active delivery system for Yang’s nanoparticles. The same technology is also likely to be effective for infectious or other diseases, as well as for tissue regeneration, Dong said.
In the first proof of their technology, the two research groups targeted circulating melanoma cells. In a paper published in the current online issue of the journal Small, titled “Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting,” the researchers report the use of a novel biodegradable and photoluminescent poly (lactic acid) (BPLP-PLA) nanoparticle, loaded with melanoma-specific drugs with immune cells as the nanoparticle carriers. They showed that the immune cells could bind to the melanoma cells under shear stress conditions similar to those in the bloodstream. These experiments were all performed outside the body. Next they intend to perform studies in animal models and in solid tumors.
“This is the first study and is just to show that the technology works,” Dong said. “This study is not about curing melanoma. There are probably other ways to do that. We used melanoma cells to validate the approach.”
[osd_subscribe categories=’drug-delivery’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “DRUG DELIVERY”‘]
Receive an email update when we add a new DRUG DELIVERY article.
The Latest on: Nanoparticle drug delivery
[google_news title=”” keyword=”nanoparticle drug delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Nanoparticle drug delivery
- Global Lipid Nanoparticles Industry is expected to maintain a 14.2% CAGR from 2023 to 2033, per FMI’s analysison November 26, 2023 at 8:43 pm
It is projected that the global lipid nanoparticles industry size will be valued at US$ 877.8 million in 2023. The market is expected to expand at a CAGR of 14.2% between 2023 and 2033, reaching ...
- New hydrogel jabs to reduce daily diabetes shots to just 3 a yearon November 24, 2023 at 5:03 pm
Researchers have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro, Trulicity, Victoza, and others ...
- Drug Delivery System Could Reduce Daily Diabetes Injections to Three a Yearon November 23, 2023 at 1:19 am
A novel hydrogel drug delivery system could reduce daily or weekly injections of weight control drugs for diabetic patients to once every four months.
- New Grant Supports Study of Nanoparticle-Based Cancer Therapieson November 20, 2023 at 6:02 am
A new grant will support scientists in investigating how nanoparticles interact with the immune system and cancer so that new drug delivery systems can be developed.
- Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size, Trends & Opportunities, Research Report 2024 -2031on November 19, 2023 at 12:59 pm
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market (2024-2031) report enlists a variety of qualitative as well as quantitative research findings and remarkable insights associated ...
- Unraveling the immune system's response to nanoparticle drug deliveryon November 17, 2023 at 5:21 pm
To reduce the side effects associated with chemotherapy treatments, researchers have investigated the use of delivery systems that can take more drugs directly to the tumor. Ninh (Irene) La-Beck, ...
- Using AI to Create More Precise and Personalized Drug Delivery Solutionson November 16, 2023 at 7:36 am
With two NIH Awards totaling $2.8 million, Daniel Reker of Duke BME will design machine learning models to improve the development of more effective drug delivery tools.
- Researchers develop nanoparticle treatment approach for optimized pancreatic cancer therapyon November 15, 2023 at 7:52 am
Pancreatic cancer is one of the deadliest types of cancers in humans. It is the fourth leading cause of cancer-related deaths in the western world. The early stages of the disease often progress ...
- Lipid Nanoparticles CDMO Market (Nucleic Acids LNPs) worth $450.2 Mn by 2030 - Exclusive Report by InsightAce Analyticon November 13, 2023 at 11:44 am
Lipid Nanoparticles CDMO Market Nucleic Acids LNPs worth 4502 Mn by 2030 ndash Exclusive Report by InsightAce Analytic ...
via Bing News